BioRender Template

Ovarian Cancer SYK -EGFR -CDC6 Pathway

Created by

Jayaprakash Mandal

Use This Template – Free

No credit card required to sign up.

This template is fully editable in BioRender

Swap in different text, shapes, & icons
Recolor and rearrange every icon, line, & label
Export or share for any use case

Join 4M+ scientists already making publication-ready figures

Description: The graphical abstract shows ovarian cancer cells developing resistance to Carboplatin/Paclitaxel, marked by increased SYK and EGFR. This resistance involves EGFR and ERBB2 phosphorylation, activating SYK and ERK1/2-MAPK, leading to tumor growth. Combining SYK inhibitor (R406) and EGFR inhibitor (Lapatinib) inhibits CDC6 transcription, disrupts DNA replication, and induces apoptosis, effectively targeting drug-resistant ovarian cancer cells and offering a potential therapeutic strategy.

BioRender icons and templates meet journal, grant, and copyright standards. For AI-generated figures, policies vary. Learn More

Not quite the right template? Discover more.

Search thousands of templates across 30+ life-science fields.

Newest templates

ELISA - Reaction View - Indirect - Fluorescent

Hallmarks of Aging (Circle Layout)

ELISA Smart Protocol

ELISA - Well View - Competitive - Antibody - Antibody-labeled - Fluorescent

ELISA - Well View - Competitive - Antibody - Antibody-labeled - Chemiluminescent

ELISA - Well View - Competitive - Antibody - Antibody-labeled - Colorimetric - Conjugated

ELISA - Well View - Competitive - Antibody - Antibody-labeled - Colorimetric - Unconjugated

ELISA - Well View - Competitive - Antigen - Antibody-labeled - Fluorescent

BioRender Template FAQs

What does the Ovarian Cancer SYK -EGFR -CDC6 Pathway template show?

The graphical abstract shows ovarian cancer cells developing resistance to Carboplatin/Paclitaxel, marked by increased SYK and EGFR. This resistance involves EGFR and ERBB2 phosphorylation, activating SYK and ERK1/2-MAPK, leading to tumor growth. Combining SYK inhibitor (R406) and EGFR inhibitor (Lapatinib) inhibits CDC6 transcription, disrupts DNA replication, and induces apoptosis, effectively targeting drug-resistant ovarian cancer cells and offering a potential therapeutic strategy.

Is the Ovarian Cancer SYK -EGFR -CDC6 Pathway template free to use?

Yes, you can customize this template with a free BioRender account (no credit card required). Paid plans unlock additional export formats, higher-resolution downloads, and publication permissions.

Can I edit or customize this template?

Yes, every element is fully editable. Icons, labels, colors, arrows, shapes and layout can all be changed to match your preferences or needs using BioRender's drag-and-drop editor. You can add or remove elements to fully customize your use case.

Is this template accepted for use in journals, theses, or grant applications?

Yes, BioRender icons and templates meet journal, grant, and copyright standards for publication, and many researchers cite BioRender directly in their figure legends.

How do I cite BioRender if I use this template?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

What is Ovarian Cancer SYK -EGFR -CDC6 Pathway used for / who typically uses this template?

Researchers and scientists use this template for publications, funding proposals, grant applications, presentations, posters, and more.